142167-38-2

Basic information

• Product Name: 5-Bromo-4-chlorosalicylic acid
• Synonyms: 5-Bromo-4-chloro-2-hydroxybenzoic acid 96%;5-Bromo-4-chlorosalicylic acid;5-Bromo-4-chloro-2-hydroxybenzoic acid;5-Bromo-4-chloro-2-hydroxybenzoicacid96%
• CAS NO: 142167-38-2
• Molecular Formula: C₇H₄BrClO₃
• Molecular Weight: 251.47
• Product Categories: blocks;Bromides;Carboxes
• Mol File: 142167-38-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 370.8 °C at 760 mmHg
• Flash Point: 178 °C
• Appearance: /
• Density: 1.956 g/cm³
• Vapor Pressure: 3.74E-06mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Bromo-4-chlorosalicylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-4-chlorosalicylic acid(142167-38-2)
• EPA Substance Registry System: 5-Bromo-4-chlorosalicylic acid(142167-38-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 142167-38-2(Hazardous Substances Data)

Usage

General Description

5-Bromo-4-chlorosalicylic acid is a chemical compound that belongs to the salicylic acid derivative family. It is a white to yellowish crystalline powder with a molecular formula of C7H4BrClO4 and a molecular weight of 257.47 g/mol. 5-Bromo-4-chlorosalicylic acid is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also utilized in the manufacturing of dyes, pigments, and other organic chemicals. Additionally, 5-Bromo-4-chlorosalicylic acid has antimicrobial properties and is used in the development of antimicrobial agents. Overall, this chemical plays a crucial role in various industrial and scientific applications due to its unique chemical properties and versatility.

InChI:InChI=1/C7H4BrClO3/c8-4-1-3(7(11)12)6(10)2-5(4)9/h1-2,10H,(H,11,12)

Upstream product

• 55488-81-8 methyl 5-bromo-4-chloro-2-hydroxybenzoate 
• 5106-98-9 4-chlorosalicylic acid 

Downstream Products

• 55488-81-8 methyl 5-bromo-4-chloro-2-hydroxybenzoate 
• 1070892-82-8 5-bromo-2-(3-tert-butoxycarbonyl-propoxy)-4-chloro-benzoic acid 2-trimethylsilanyl-ethyl ester 
• 1070892-81-7 5-bromo-2-(3-tert-butoxycarbonyl-propoxy)-4-chloro-benzoic acid 
• 1070892-88-4 5-bromo-4-chloro-2-(3-cyano-propoxy)-N-(2-methoxy-phenyl)-N-methyl-benzamide 
• 1070892-87-3 5-bromo-4-chloro-2-hydroxy-N-(2-methoxy-phenyl)-N-methyl-benzamide 
• 1070892-80-6 5-bromo-2-(3-tert-butoxycarbonyl-propoxy)-4-chloro-benzoic acid 3-tert-butoxycarbonyl-propyl ester 
• 142167-44-0 4,5-dibromo-2-hydroxybenzoic acid 
• 1026449-11-5 5-bromo-4-chloro-2-hydroxybenzamide 
• 162270-27-1 2-(5-bromo-4-chloro-α-cyano-2-methoxymethoxybenzyl)-3-methoxymethoxypyridine 
• 162271-18-3 2-(5-bromo-4-chloro-2-methoxymethoxybenzoyl)-3-methoxymethoxypyridine 
• 162267-42-7 (5-Bromo-4-chloro-2-hydroxy-phenyl)-(3-hydroxy-pyridin-2-yl)-methanone O-tert-butyl-oxime 
• 162269-62-7 2-(5-bromo-4-chloro-2-hydroxybenzoyl)-3-hydroxypyridine 
• 162269-96-7 5-bromo-4-chloro-2-methoxymethoxybenzyl cyanide 
• 162269-95-6 5-bromo-4-chloro-2-methoxymethoxybenzyl alcohol 

Relevant articles and documents

INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity

Salicylanilides have proved their activity against tuberculosis (TB). One weak electron-withdrawing substituent is favored at the salicylic part, specially Cl or Br atoms at positions 4 or 5. On the other hand, the antimycobacterial activity of salicylanilides is negatively affected when a strong electron-withdrawing substituent ([sbnd]NO2) is present at the same positions. Herein we describe the synthesis and characterization of novel salicylanilides possessing two weak electron-withdrawing groups (halogen atoms) at their salicylic part and compare their antitubercular activity with their monohalogenated analogues. All dihalogenated derivatives proved to possess antitubercular activity at a very narrow micromolar range (MIC?=?1–4?μM), similar with their most active monohalogenated analogues. More importantly, the most active final molecules were further screened against multidrug resistant strains and found to inhibit their growth at the range of 0.5–4?μM.

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).